

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. (Currently amended) A pharmaceutical composition for treating an infection in an animal, said composition comprising:

- (a) at least one antimicrobial compound, comprising an organic phenolic compound reacted with at least one Group I salt; and
- (b) a pharmaceutically acceptable carrier for parenteral administration.

2. Cancelled

3. Cancelled

4. (Currently amended) The pharmaceutical composition of claim 1 ~~[[2]]~~ wherein the organic phenolic compound is selected from isopropyl-o-cresol, isopropyl-cresol and combinations thereof.

5. (Currently amended) The pharmaceutical composition of claim 1 ~~[[3]]~~ wherein one of the at least one Group I salt base is a Group I hydroxide base.

6. (Original) The pharmaceutical composition of claim 5 wherein the Group I base is selected from sodium hydroxide, potassium hydroxide and combinations thereof.

7. (Original) The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises isopropyl-o-cresol and isopropyl-cresol chemically reacted with sodium hydroxide and potassium hydroxide.

8. (Currently Amended) The pharmaceutical composition of claim 1 comprising from 0.1wt% of the pharmaceutical composition to 15wt% of the pharmaceutical composition of antimicrobial compound.

9. (Currently Amended) The pharmaceutical composition of claim 1 comprising from 0.1wt% of the pharmaceutical composition to 15wt% of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous, intradermal, or intramuscular administration.

10. (Currently Amended) The pharmaceutical composition of claim 1 comprising from 3.5wt% of the pharmaceutical composition to 10wt% of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises a vegetable oil.

11. (Original) The pharmaceutical composition of claim 10 wherein the pharmaceutically acceptable carrier comprises olive oil.

12. (Currently Amended) The pharmaceutical composition of claim 1 comprising from 0.1wt% of the pharmaceutical composition to 1.0wt% of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.

13. (Currently Amended) The pharmaceutical composition of claim 12 comprising from 0.5wt% of the pharmaceutical composition to 0.8wt% of the pharmaceutical composition of antimicrobial compound, wherein the pharmaceutically acceptable carrier comprises 0.5wt% of the pharmaceutically acceptable carrier to 1.0wt% of the pharmaceutically acceptable carrier of sodium chloride.

14. (Currently Amended) The pharmaceutical composition of claim 4 wherein the antimicrobial compound comprises isopropyl-o-cresol and isopropyl cresol and wherein there is more isopropyl-o-cresol than isopropyl cresol.

15. (Currently Amended) The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises between 55wt% of the antimicrobial compound and 99wt% of the antimicrobial compound of isopropyl-o-cresol or base reacted isopropyl-o-cresol and between 1wt% of the antimicrobial compound and 45wt% of the antimicrobial compound of isopropyl cresol or base reacted isopropyl cresol.

16. (Currently Amended) The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises between 75wt% of the antimicrobial compound and 99wt% of the antimicrobial compound of isopropyl-o-cresol or base reacted isopropyl-o-cresol and between 1wt% of the antimicrobial compound and 25wt% of the antimicrobial compound of isopropyl cresol or base reacted isopropyl cresol.

17. (Currently Amended) The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises between 90wt% of the antimicrobial compound and 99wt% of the antimicrobial compound of isopropyl-o-cresol or base reacted isopropyl-o-cresol and between 1wt% of the antimicrobial compound and 10wt% of the antimicrobial compound of isopropyl cresol or base reacted isopropyl cresol.

18. (Currently Amended) The pharmaceutical composition of claim 1 wherein the antimicrobial compound comprises between 95wt% of the antimicrobial compound and 99wt% of the antimicrobial compound of isopropyl-o-cresol or base reacted isopropyl-o-cresol and between 1wt% of the antimicrobial compound and 5wt% of the antimicrobial compound of isopropyl cresol or base reacted isopropyl cresol.

19. (Original) The pharmaceutical composition of claim 1 wherein the animal is selected from humans, horses, cows, pigs, sheep, goats, rabbits, dogs, cats, chickens, turkeys, ducks and birds.

20. (Original) The pharmaceutical composition of claim 1 wherein the infection comprises infection by *E. coli*, *Salmonella* spp, *Pasteurella* spp., *Staphylococcus* spp.,

*Streptococcus* spp., *Corinebacterium* spp., *Bacillus* spp., *Clostridium* spp., *Spherophorus* spp., *Candida* spp., *Trychophyton* spp., *Microsporum* spp., *Micobacterium* spp., *Cryptosporidia* spp., *Microsporidia* spp., *Listeria monocytogenes*, *Lawsonia intracellularis*, *Treponema desyneriae*, *Enterococcus* spp., *Heamophylus* spp., *Campylobacter* spp., *Chlamydia*, *Brucella* spp., or *Vibrio* spp.

21-36. Cancelled